This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks Slip Slightly Ahead of Apple Earnings; Biotech Drags on Nasdaq

NEW YORK (TheStreet) -- Stocks drifted lower on Monday afternoon in anticipation of Apple's (AAPL) earnings after the bell and the kickoff to the Federal Reserve's two-day meeting on Tuesday. 

The S&P 500 was down 0.17%, the Dow Jones Industrial Average slid 0.05%, and the Nasdaq fell 0.48%. The S&P 500 and Nasdaq moved away from all-time highs set on Friday.

Apple (AAPL) was one of the best performers on the Dow ahead of its quarterly results. Investors are keen to see whether growth in iPad sales has been sustained and they will monitor the scale of demand for larger iPhones in China. Apple shares added nearly 2%.

The Federal Reserve will convene for its monthly two-day meeting on Tuesday. The central bank is widely expected to maintain its crisis-level interest rate policy for another month, though its statement on Wednesday will be closely examined for clues as to when a hike could occur.

"The market has held to the gains made last week off of what has been, frankly, a wait-and-see overnight session with little data or concrete news to speak of," said CRT Capital's David Ader. "In the U.S. we wait for the FOMC with low expectations and really turn attention to (nonfarm payrolls) next week if we can sidestep overseas events."

Biotech companies weighed on the Nasdaq, following the lead of Mylan (MYL - Get Report) and Teva Pharmaceuticals (TEVA). The two were lower after Mylan rejected a $40 billion bid from Teva. Celldex (CLDX)Biogen (BIIB) and Celgene (CELG) were all lower, while the Health Care SPDR ETF (XLV) declined 1.3% and the iShares Nasdaq Biotechnology Index ETF (IBB) fell 3.6%.

Biotech company Celladon (CLDN) tanked nearly 81% after a trial of its heart failure treatment missed its primary and secondary endpoints.

Google (GOOGL) shares were also pressuring markets after the company announced an experimental program to purchase patents. The tech giant plans to create a marketplace that will counteract patent troll attacks. The company didn't outline the types of patents nor how many it intended to purchase. Shares fell 1.3%.

DuPont (DD - Get Report) was the leading gainer on the Dow, adding more than 4% as activist investor Trian Fund Management zeroed in on two board seats. Influential proxy adviser Institutional Shareholder Services recommended Trian's Nelson Peltz and John Myers for the positions. 

Applied Materials  (AMAT) and Tokyo Electron called off their $29 billion merger following problems with the U.S. Justice Department and regulatory issues in several different countries. Applied Materials plummeted 7.5%, the worst performer on the Nasdaq and S&P 500.

Deutsche Bank (DB) tumbled 4.5% after reporting first-quarter profit half that of a year earlier as legal expenses ate into earnings. The German bank also unveiled a strategic overhaul which will target 3.5 billion euros in annual savings.

HSBC (HSBC) jumped 3.3% on reports it was considering spinning off its U.K. retail banking unit. The bank could make around $30 billion if a deal came to pass, according to the Sunday Times.

SeaWorld (SEAS) jumped to an eight-month high after Goldman Sachs upgraded on the belief sentiment should begin to improve soon. The theme park operator has been suffering poor publicity over its treatment of killer whales.

French tech and outsourcing company Capgemini agreed to purchase iGate (IGTE) for $4 billion on Monday. An estimated $75 million in annual cost savings is expected within the first three years. iGate shares spiked 3.5%.

Growth in the U.S. services sector unexpectedly cooled in April, according to the latest figures from Markit. The Purchasing Managers Index for the services sector fell to 57.8 in April from 59.2 in March. Economists had expected an increase to 59.5.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DD $74.77 4.50%
MYL $71.82 -5.60%
AAPL $131.68 1.10%
FB $82.20 0.83%
GOOG $556.33 -1.50%

Markets

DOW 18,081.11 +0.97 0.01%
S&P 500 2,112.41 -5.28 -0.25%
NASDAQ 5,062.5960 -29.4890 -0.58%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs